M.D. Anderson Cancer Center: Hematologic Diseases trials

The registry lists 10 Hematologic Diseases studies with M.D. Anderson Cancer Center as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 2 9No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)TerminatedNCT01924169Phase 2Results posted
• Dexamethasone Dyspnea StudyCompletedNCT01670097Phase 2Results posted
• Ondansetron Versus Aprepitant Plus Ondansetron for EmesisCompletedNCT00954941Phase 2Results posted
• Busulfan and Fludarabine Followed by Post-transplant CyclophosphamideCompletedNCT00800839Phase 2Results posted
• Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic DisordersWithdrawnNCT05293509Phase 2
• Itacitinib for the Prevention of Graft Versus Host DiseaseActive, not recruitingNCT04859946Phase 2
• Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell TransplantationWithdrawnNCT04127721Phase 2
• AZA + Venetoclax as Maintenance Therapy in Patients With AML in RemissionTerminatedNCT04062266Phase 2
• SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)Active, not recruitingNCT01352520Phase 2
• Patient-Reported Outcomes Version of Common Terminology Criteria (CTCPRO) Cognitive DebriefingCompletedNCT00909207